PYC Other Current Liab vs Current Deferred Revenue Analysis

PYC Stock

1.40 0.05 3.45%

PYC Therapeutics financial indicator trend analysis is much more than just breaking down PYC Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PYC Therapeutics is a good investment. Please check the relationship between PYC Therapeutics Other Current Liab and its Current Deferred Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PYC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Other Current Liab vs Current Deferred Revenue

Other Current Liab vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PYC Therapeutics Other Current Liab account and Current Deferred Revenue. At this time, the significance of the direction appears to have very week relationship.

The correlation between PYC Therapeutics' Other Current Liab and Current Deferred Revenue is 0.26. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of PYC Therapeutics, assuming nothing else is changed. The correlation between historical values of PYC Therapeutics' Other Current Liab and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of PYC Therapeutics are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Other Current Liab i.e., PYC Therapeutics' Other Current Liab and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.26

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Other Current Liab

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from PYC Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PYC Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PYC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Issuance Of Capital Stock is likely to gain to about 96.7 M in 2024, whereas Selling General Administrative is likely to drop slightly above 2.6 M in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	839.5K	882.0K	1.1M	1.1M
Cost Of Revenue	839.5K	882.0K	1.1M	1.5M

Depreciation And Amortization Cost Of Revenue

PYC Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Accounts Payable	Cash	Net Receivables	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Property Plant And Equipment Gross	Total Current Assets	Short Long Term Debt Total	Short Term Debt	Other Liab
Total Assets		0.55	0.88	1.0	0.9	0.95	0.83	0.91	-0.05	0.98	0.82	0.91	0.82	-0.94	-0.93	0.86	0.98	0.87	0.73	0.79	-0.73	0.95	1.0	0.25	0.87	0.51
Other Current Liab	0.55		0.79	0.51	0.65	0.46	0.8	0.77	0.02	0.63	0.62	0.61	0.26	-0.46	-0.71	0.67	0.4	0.62	0.55	0.22	-0.57	0.74	0.52	-0.15	0.62	0.27
Total Current Liabilities	0.88	0.79		0.85	0.98	0.88	0.97	1.0	-0.09	0.93	0.65	0.75	0.77	-0.88	-0.94	0.71	0.79	0.76	0.68	0.74	-0.55	0.93	0.88	0.06	0.75	0.47
Total Stockholder Equity	1.0	0.51	0.85		0.88	0.94	0.8	0.89	-0.05	0.97	0.82	0.91	0.82	-0.94	-0.91	0.85	0.99	0.86	0.72	0.79	-0.73	0.94	1.0	0.27	0.86	0.51
Accounts Payable	0.9	0.65	0.98	0.88		0.94	0.94	0.98	-0.07	0.94	0.59	0.72	0.85	-0.93	-0.94	0.65	0.83	0.75	0.65	0.85	-0.48	0.91	0.91	0.15	0.72	0.51
Cash	0.95	0.46	0.88	0.94	0.94		0.87	0.9	-0.09	0.95	0.65	0.78	0.94	-1.0	-0.9	0.68	0.92	0.75	0.68	0.92	-0.5	0.89	0.96	0.3	0.76	0.45
Net Receivables	0.83	0.8	0.97	0.8	0.94	0.87		0.97	-0.13	0.89	0.63	0.73	0.78	-0.87	-0.91	0.68	0.72	0.72	0.7	0.72	-0.47	0.91	0.83	0.06	0.76	0.39
Total Liab	0.91	0.77	1.0	0.89	0.98	0.9	0.97		-0.09	0.95	0.69	0.79	0.78	-0.9	-0.95	0.75	0.83	0.79	0.7	0.75	-0.59	0.95	0.91	0.09	0.78	0.48
Intangible Assets	-0.05	0.02	-0.09	-0.05	-0.07	-0.09	-0.13	-0.09		0.06	0.13	0.07	-0.25	0.14	-0.13	-0.01	-0.08	0.29	-0.15	-0.05	-0.03	-0.06	-0.09	0.76	-0.02	0.3
Common Stock	0.98	0.63	0.93	0.97	0.94	0.95	0.89	0.95	0.06		0.78	0.88	0.81	-0.93	-0.98	0.82	0.93	0.91	0.7	0.8	-0.66	0.95	0.97	0.29	0.87	0.58
Property Plant Equipment	0.82	0.62	0.65	0.82	0.59	0.65	0.63	0.69	0.13	0.78		0.98	0.4	-0.64	-0.77	0.96	0.78	0.87	0.69	0.35	-0.93	0.86	0.78	0.26	0.9	0.31
Property Plant And Equipment Net	0.91	0.61	0.75	0.91	0.72	0.78	0.73	0.79	0.07	0.88	0.98		0.58	-0.77	-0.85	0.96	0.88	0.9	0.75	0.53	-0.88	0.93	0.89	0.28	0.93	0.36
Current Deferred Revenue	0.82	0.26	0.77	0.82	0.85	0.94	0.78	0.78	-0.25	0.81	0.4	0.58		-0.94	-0.74	0.47	0.81	0.54	0.59	0.96	-0.24	0.72	0.85	0.21	0.59	0.35
Net Debt	-0.94	-0.46	-0.88	-0.94	-0.93	-1.0	-0.87	-0.9	0.14	-0.93	-0.64	-0.77	-0.94		0.89	-0.68	-0.92	-0.73	-0.7	-0.91	0.5	-0.89	-0.96	-0.28	-0.77	-0.43
Retained Earnings	-0.93	-0.71	-0.94	-0.91	-0.94	-0.9	-0.91	-0.95	-0.13	-0.98	-0.77	-0.85	-0.74	0.89		-0.8	-0.86	-0.92	-0.7	-0.73	0.64	-0.94	-0.92	-0.31	-0.87	-0.61
Non Current Assets Total	0.86	0.67	0.71	0.85	0.65	0.68	0.68	0.75	-0.01	0.82	0.96	0.96	0.47	-0.68	-0.8		0.82	0.88	0.68	0.4	-0.93	0.87	0.83	0.11	0.89	0.4
Cash And Short Term Investments	0.98	0.4	0.79	0.99	0.83	0.92	0.72	0.83	-0.08	0.93	0.78	0.88	0.81	-0.92	-0.86	0.82		0.82	0.68	0.79	-0.73	0.89	0.99	0.26	0.83	0.5
Common Stock Total Equity	0.87	0.62	0.76	0.86	0.75	0.75	0.72	0.79	0.29	0.91	0.87	0.9	0.54	-0.73	-0.92	0.88	0.82		0.57	0.54	-0.78	0.86	0.84	0.38	0.88	0.69
Common Stock Shares Outstanding	0.73	0.55	0.68	0.72	0.65	0.68	0.7	0.7	-0.15	0.7	0.69	0.75	0.59	-0.7	-0.7	0.68	0.68	0.57		0.52	-0.58	0.78	0.72	0.14	0.77	0.13
Other Current Assets	0.79	0.22	0.74	0.79	0.85	0.92	0.72	0.75	-0.05	0.8	0.35	0.53	0.96	-0.91	-0.73	0.4	0.79	0.54	0.52		-0.19	0.67	0.82	0.34	0.5	0.37
Other Stockholder Equity	-0.73	-0.57	-0.55	-0.73	-0.48	-0.5	-0.47	-0.59	-0.03	-0.66	-0.93	-0.88	-0.24	0.5	0.64	-0.93	-0.73	-0.78	-0.58	-0.19		-0.76	-0.7	-0.09	-0.79	-0.33
Property Plant And Equipment Gross	0.95	0.74	0.93	0.94	0.91	0.89	0.91	0.95	-0.06	0.95	0.86	0.93	0.72	-0.89	-0.94	0.87	0.89	0.86	0.78	0.67	-0.76		0.94	0.16	0.9	0.41
Total Current Assets	1.0	0.52	0.88	1.0	0.91	0.96	0.83	0.91	-0.09	0.97	0.78	0.89	0.85	-0.96	-0.92	0.83	0.99	0.84	0.72	0.82	-0.7	0.94		0.23	0.85	0.5
Short Long Term Debt Total	0.25	-0.15	0.06	0.27	0.15	0.3	0.06	0.09	0.76	0.29	0.26	0.28	0.21	-0.28	-0.31	0.11	0.26	0.38	0.14	0.34	-0.09	0.16	0.23		0.25	0.27
Short Term Debt	0.87	0.62	0.75	0.86	0.72	0.76	0.76	0.78	-0.02	0.87	0.9	0.93	0.59	-0.77	-0.87	0.89	0.83	0.88	0.77	0.5	-0.79	0.9	0.85	0.25		0.45
Other Liab	0.51	0.27	0.47	0.51	0.51	0.45	0.39	0.48	0.3	0.58	0.31	0.36	0.35	-0.43	-0.61	0.4	0.5	0.69	0.13	0.37	-0.33	0.41	0.5	0.27	0.45

Click cells to compare fundamentals

PYC Therapeutics Account Relationship Matchups

PYC Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	31.5M	57.9M	45.4M	37.2M	91.2M	95.8M
Other Current Liab	455.3K	763.3K	1.6M	3.3M	1.3M	1.3M
Total Current Liabilities	705.6K	3.3M	4.4M	8.4M	9.1M	9.6M
Total Stockholder Equity	28.5M	53.0M	39.4M	27.7M	80.5M	84.5M
Accounts Payable	97.3K	2.3M	2.6M	4.9M	7.5M	7.9M
Cash	7.2M	18.4M	29.1M	15.6M	66.9M	70.2M
Net Receivables	82.7K	185.6K	10.1M	16.3M	18.0M	18.9M
Total Liab	1.4M	4.0M	5.1M	8.7M	10.2M	10.7M
Common Stock	62.0M	87.2M	126.0M	140.1M	230.6M	242.1M
Property Plant Equipment	1.1M	1.5M	1.6M	1.0M	1.2M	1.3M
Property Plant And Equipment Net	1.1M	1.5M	1.6M	1.0M	1.6M	1.7M
Net Debt	(6.4M)	(17.7M)	(28.2M)	(15.3M)	(65.8M)	(62.5M)
Retained Earnings	(63.7M)	(81.5M)	(95.4M)	(118.2M)	(155.9M)	(148.1M)
Non Current Assets Total	6.0M	6.2M	6.1M	5.3M	5.6M	5.9M
Cash And Short Term Investments	25.4M	51.5M	29.1M	15.6M	66.9M	70.2M
Liabilities And Stockholders Equity	31.5M	57.9M	45.4M	37.2M	91.2M	95.8M
Other Current Assets	50.4K	93.1K	68.4K	49.6K	744.0K	781.2K
Other Stockholder Equity	(23.5M)	(44.5M)	(30.6M)	(21.9M)	(19.7M)	(18.7M)
Property Plant And Equipment Gross	1.1M	3.5M	4.3M	4.2M	5.6M	5.9M
Total Current Assets	25.6M	51.8M	39.2M	31.9M	85.6M	89.9M
Accumulated Other Comprehensive Income	5.0M	8.6M	8.7M	5.8M	5.8M	6.1M
Short Long Term Debt Total	798.1K	730.4K	943.8K	315.5K	1.1M	699.4K
Non Currrent Assets Other	(4.9M)	(6.0M)	23.6K	(5.3M)	4.1M	4.3M
Net Tangible Assets	23.1M	48.4M	34.9M	23.5M	27.0M	17.3M
Long Term Debt Total	645.2K	542.8K	684.0K	137.7K	158.3K	315.8K
Net Invested Capital	28.0M	52.5M	39.4M	27.7M	80.5M	84.5M
Cash And Equivalents	7.2M	18.4M	29.1M	15.6M	17.9M	14.1M
Net Working Capital	24.6M	48.5M	34.9M	23.5M	76.5M	80.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for PYC Stock Analysis

When running PYC Therapeutics' price analysis, check to measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC